Kowa Research Institute, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1981-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.kowaus.com
Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02922465
Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia
Phase 3
Withdrawn
- Conditions
- HyperlipidemiaDyslipidemia
- Interventions
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Kowa Research Institute, Inc.
- Registration Number
- NCT02799758
Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02719431
Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects
Phase 1
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Drug: K-312 25 mg QDDrug: K-312 50 mg QDDrug: K-312 100 mg QDDrug: K-312 200 mg QDDrug: K-312 400 mg QDDrug: K-312 10 mg QDOther: Placebo
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02676596
Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312
Phase 1
Completed
- Conditions
- Dyslipidemia
- Interventions
- Drug: K-312 100 mgDrug: K-312 100 ug C14 IV
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02676830
Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia
Phase 3
Withdrawn
- Conditions
- HyperlipidemiaDyslipidemia
- Interventions
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Kowa Research Institute, Inc.
- Registration Number
- NCT02670434
A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Hyperlipidemia
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02634034
Drug-Drug Interaction Study in Healthy Adult Volunteers
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02275962
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Drug-Drug Interaction Study in Healthy Adult Volunteers
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02275988
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Drug-Drug Interaction Study in Healthy Adult Volunteers
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02276001
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath